STOCK TITAN

Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Singular Genomics Systems (Nasdaq: OMIC) has received a non-binding acquisition proposal from Deerfield Management Company and affiliated funds. The offer is to acquire all outstanding shares not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder, plans to invite other major stockholders and management to rollover their shares into the new company.

A special committee of independent directors, previously formed to evaluate strategic alternatives, will consider this proposal. The company emphasizes that there's no assurance of any transaction being consummated. TD Cowen is serving as the financial advisor to the special committee, with legal advisors also appointed.

Singular Genomics Systems (Nasdaq: OMIC) ha ricevuto una proposta di acquisizione non vincolante da Deerfield Management Company e fondi affiliati. L'offerta prevede l'acquisto di tutte le azioni straordinarie non già possedute da Deerfield per 10,00 $ per azione in contante. Deerfield, un azionista esistente, prevede di invitare altri principali azionisti e la gestione a convertire le loro azioni nella nuova società.

Un comitato speciale di amministratori indipendenti, precedentemente costituito per valutare alternative strategiche, prenderà in considerazione questa proposta. L'azienda sottolinea che non c'è alcuna garanzia che la transazione venga conclusa. TD Cowen funge da consulente finanziario per il comitato speciale, con consulenti legali già nominati.

Singular Genomics Systems (Nasdaq: OMIC) ha recibido una propuesta de adquisición no vinculante de Deerfield Management Company y fondos afiliados. La oferta es para adquirir todas las acciones en circulación que no son ya propiedad de Deerfield por $10.00 por acción en efectivo. Deerfield, un accionista existente, planea invitar a otros importantes accionistas y a la dirección a reinvertir sus acciones en la nueva empresa.

Un comité especial de directores independientes, previamente formado para evaluar alternativas estratégicas, considerará esta propuesta. La compañía enfatiza que no hay ninguna garantía de que se complete alguna transacción. TD Cowen actúa como asesor financiero del comité especial, con asesores legales también nombrados.

싱귤라 젠오믹스 시스템즈(나스닥: OMIC)는 Deerfield Management Company와 그 계열사들로부터 비구속적 인수 제안을 받았습니다. 이 제안은 Deerfield가 이미 소유하지 않은 모든 유통 주식을 주당 10.00달러 현금으로 인수하는 것입니다. Deerfield는 기존 주주로서 다른 주요 주주들과 경영진을 초대하여 그들의 주식을 새로운 회사로 전환할 계획입니다.

전략적 대안을 평가하기 위해 이전에 구성된 독립 이사진의 특별 위원회가 이 제안을 고려할 것입니다. 회사는 거래 성사에 대한 보장이 없음을 강조합니다. TD Cowen은 특별 위원회의 재무 고문으로 활동하며, 법률 고문도 임명되었습니다.

Singular Genomics Systems (Nasdaq: OMIC) a reçu une proposition d'acquisition non contraignante de Deerfield Management Company et de fonds affiliés. L'offre porte sur l'acquisition de toutes les actions en circulation qui ne sont pas déjà détenues par Deerfield pour 10,00 $ par action en espèces. Deerfield, un actionnaire existant, prévoit d'inviter d'autres grands actionnaires et la direction à réinvestir leurs actions dans la nouvelle société.

Un comité spécial de directeurs indépendants, précédemment constitué pour évaluer des alternatives stratégiques, examinera cette proposition. L'entreprise souligne qu'il n'y a aucune garantie qu'une transaction soit conclue. TD Cowen agit en tant que conseiller financier pour le comité spécial, des conseillers juridiques ayant également été nommés.

Singular Genomics Systems (Nasdaq: OMIC) hat ein nicht verbindliches Übernahmeangebot von Deerfield Management Company und zugehörigen Fonds erhalten. Das Angebot sieht vor, alle ausstehenden Aktien, die noch nicht im Besitz von Deerfield sind, für 10,00 $ pro Aktie in bar zu erwerben. Deerfield, ein bestehender Aktionär, plant, andere wichtige Aktionäre und das Management einzuladen, ihre Aktien in das neue Unternehmen zu übertragen.

Ein Sonderausschuss unabhängiger Direktoren, der zuvor zur Bewertung strategischer Alternativen gebildet wurde, wird diesen Vorschlag prüfen. Das Unternehmen betont, dass es keine Garantie dafür gibt, dass eine Transaktion abgeschlossen wird. TD Cowen fungiert als Finanzberater des Sonderausschusses, und es wurden auch juristische Berater benannt.

Positive
  • Potential acquisition offer at $10.00 per share in cash, providing a clear valuation
  • Existing stockholder (Deerfield) showing confidence in the company through acquisition proposal
  • Special committee already in place to evaluate strategic alternatives, including this proposal
Negative
  • Non-binding nature of the proposal introduces uncertainty
  • Potential loss of independence for Singular Genomics if acquired
  • Possible shareholder concerns about the fairness of the $10.00 per share offer

Insights

Deerfield's non-binding proposal to acquire Singular Genomics at $10.00 per share represents a significant development. The offer price implies a premium of approximately 67% over the company's closing price of $5.99 on September 11, 2024. This substantial premium suggests Deerfield sees untapped value in Singular Genomics' NGS and spatial multiomics technologies. However, investors should note that this is a non-binding proposal and there's no guarantee of a deal. The formation of a Special Committee to evaluate strategic alternatives indicates the board is open to exploring options, which could potentially lead to a competitive bidding process. The involvement of major stockholders and existing management in the proposed transaction structure adds an interesting dynamic, potentially aligning interests but also raising questions about valuation fairness for minority shareholders.

Deerfield's interest in acquiring Singular Genomics highlights the growing importance of next-generation sequencing and spatial multiomics in the biotech landscape. These technologies are important for advancing personalized medicine and drug discovery. Singular Genomics' platforms likely offer unique capabilities that Deerfield believes can be better leveraged under private ownership. This move could potentially accelerate the development and commercialization of Singular's technologies. However, it's worth considering whether $10.00 per share fully values the long-term potential of Singular's innovations. The biotech M&A market has been heating up and this proposal could spark interest from other potential acquirers in the genomics space, possibly leading to a more competitive valuation for Singular Genomics.

The formation of a Special Committee of independent directors to evaluate strategic alternatives, including Deerfield's proposal, is a important step in ensuring shareholder interests are protected. This committee, supported by independent financial and legal advisors, will be tasked with thoroughly assessing the offer and exploring other potential options. The involvement of TD Cowen as financial advisor adds credibility to the process. However, the proposal's structure, inviting major stockholders and management to roll over their shares, raises potential conflicts of interest that the Special Committee must carefully navigate. Transparency will be key and shareholders should closely monitor any further disclosures. The committee's decision-making process and ultimate recommendation will be critical in determining whether this deal truly maximizes value for all shareholders.

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received a non-binding proposal from Deerfield Management Company, L.P. and certain affiliated funds (collectively, “Deerfield”), to acquire all of the Company’s outstanding shares of common stock that are not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company.

The Company’s board of directors previously formed a special committee of independent directors (the “Special Committee”) to evaluate and consider the Company’s strategic alternatives, which would include the proposal submitted by Deerfield.

There can be no assurance that any transaction will be consummated, whether involving Deerfield or any other party. The Company and the Special Committee do not intend to comment further about Deerfield’s proposal unless and until the Special Committee deems further disclosure is appropriate.

A copy of Deerfield’s proposal letter delivered to the Special Committee on September 5, 2024 is available as an exhibit to Deerfield’s statement of beneficial ownership on Schedule 13D, as publicly filed on Thursday, September 12, 2024, with the United States Securities and Exchange Commission.

ADVISORS

TD Cowen is serving as financial advisor to the Special Committee, Richards, Layton & Finger, P.A. is serving as the Special Committee’s outside legal advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP is serving as legal advisor to the Company.

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4® Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, the Company is currently developing the G4X™ Spatial Sequencer, which will leverage its proprietary sequencing technology, applying it as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.

Forward-looking Statements

Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. In some cases, forward-looking statements can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “foresees,” “forecasts,” “guidance,” “intends” “goals,” “may,” “might,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “targets,” “will,” “would” or similar expressions and the negatives of those terms. These forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Further information on these and additional risks that could affect Singular Genomics’ results is included in its filings with the Securities and Exchange Commission (“SEC”), including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and future reports that Singular Genomics may file with the SEC from time to time, which could cause actual results to vary from expectations. Any forward-looking statement made by Singular Genomics in this press release speaks only as of the day on which Singular Genomics makes it. Singular Genomics assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.

Investor Contact
Philip Trip Taylor
Gilmartin Group
ir@singulargenomics.com 

Media Contact
Matt Browning
pr@singulargenomics.com


FAQ

What is the acquisition offer for Singular Genomics (OMIC) stock?

Deerfield Management has proposed to acquire all outstanding shares of Singular Genomics (OMIC) not already owned by them for $10.00 per share in cash.

Is the acquisition of Singular Genomics (OMIC) by Deerfield confirmed?

No, the acquisition is not confirmed. It's a non-binding proposal that will be evaluated by a special committee of independent directors. There's no assurance that any transaction will be consummated.

Who is advising Singular Genomics (OMIC) on the potential acquisition?

TD Cowen is serving as the financial advisor to the special committee. Richards, Layton & Finger, P.A. is the special committee's legal advisor, while Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP is advising the company.

What happens to existing Singular Genomics (OMIC) shareholders if the acquisition proceeds?

Deerfield intends to invite major stockholders and existing management to rollover their shares into the new company. Other shareholders would receive $10.00 per share in cash if the deal proceeds as proposed.

Singular Genomics Systems, Inc.

NASDAQ:OMIC

OMIC Rankings

OMIC Latest News

OMIC Stock Data

36.81M
2.50M
13.9%
41.23%
0.57%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO